Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

To prevent recurrence of invasive fungal infection in patients with allogeneic stem cell transplants

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Collaborators: European Group for Blood and Marrow Transplantation; European Society for Blood and Marrow Transplantation
• Treatments: Voriconazole

Criteria

Inclusion Criteria:

• Patients with proven or probable IFI in previous 12 months receiving an allogenic stem cell transplant for any haematological disease

Exclusion Criteria:

• Pregnant or lactating women

• Severe disease other tham the underlying condition

• Active, symptomatic uncontrolled Invasive Fungal Infection

• Any evidence of active fungal disease as defined by MSG-EORTC criteria

• Concomitant use of Voriconazole 36 hours before chemotherapy until 48 hours after chemotherapy

• Other medical conditions, including HIV positive serology that would interfere with the evaluation of therapeutic response or safety of study drug